Market Cap ₹8147 Cr.
Stock P/E 44.0
P/B 7
Current Price ₹1242.5
Book Value ₹ 178.3
Face Value 10
52W High ₹1648.6
Dividend Yield 0.08%
52W Low ₹ 960
Jupiter Life Line Hospitals Ltd is a leading healthcare institution renowned for its commitment to quality patient care and medical excellence. Founded on a mission to provide comprehensive healthcare services, Jupiter Life Line Hospitals boasts a network of state-of-the-art medical facilities equipped with cutting-edge technology and staffed by a dedicated team of healthcare professionals. Specializing in a wide range of medical specialties, including cardiology, orthopedics, oncology, and more, the company prioritizes patient well-being and offers personalized treatment plans to meet each individual's unique needs. With a patient-centric approach and a reputation for delivering outstanding medical outcomes, Jupiter Life Line Hospitals Ltd is a trusted destination for those seeking top-tier healthcare services.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
#(Fig in Cr.) | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|
Net Sales | 201 | 221 | 228 | 242 | 243 | 263 | 273 | 290 |
Other Income | 2 | 3 | 2 | 3 | 5 | 4 | 8 | 9 |
Total Income | 203 | 224 | 231 | 246 | 248 | 267 | 281 | 299 |
Total Expenditure | 151 | 166 | 183 | 191 | 190 | 202 | 211 | 228 |
Operating Profit | 51 | 58 | 48 | 55 | 58 | 65 | 70 | 71 |
Interest | 10 | 10 | 11 | 11 | 12 | 12 | 1 | 1 |
Depreciation | 9 | 10 | 10 | 10 | 11 | 11 | 11 | 10 |
Exceptional Income / Expenses | -0 | -0 | 0 | -2 | -1 | -1 | -0 | 2 |
Profit Before Tax | 32 | 38 | 27 | 32 | 34 | 41 | 58 | 62 |
Provision for Tax | 2 | 11 | 27 | 16 | -20 | 8 | 14 | 17 |
Profit After Tax | 30 | 27 | -0 | 16 | 54 | 34 | 44 | 45 |
Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit After Adjustments | 30 | 27 | -0 | 16 | 54 | 34 | 44 | 45 |
Adjusted Earnings Per Share | 6 | 5.3 | -0.1 | 2.8 | 9.6 | 5.1 | 6.7 | 6.9 |
#(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
---|---|---|---|---|---|
Net Sales | 463 | 486 | 733 | 893 | 1069 |
Other Income | 2 | 4 | 4 | 10 | 26 |
Total Income | 465 | 490 | 737 | 903 | 1095 |
Total Expenditure | 380 | 419 | 580 | 691 | 831 |
Operating Profit | 84 | 71 | 157 | 212 | 264 |
Interest | 26 | 39 | 44 | 42 | 26 |
Depreciation | 26 | 31 | 36 | 39 | 43 |
Exceptional Income / Expenses | 0 | 0 | -0 | -2 | 0 |
Profit Before Tax | 33 | 2 | 77 | 129 | 195 |
Provision for Tax | 3 | 4 | 26 | 56 | 19 |
Profit After Tax | 30 | -2 | 51 | 73 | 177 |
Adjustments | 0 | 0 | 0 | 0 | 0 |
Profit After Adjustments | 30 | -2 | 51 | 73 | 177 |
Adjusted Earnings Per Share | 5.8 | -0.5 | 10.1 | 12.9 | 28.3 |
# | 1 Year | 3 Year | 5 Year | 10 Year |
---|---|---|---|---|
Sales CAGR | 22% | 24% | 0% | 0% |
Operating Profit CAGR | 35% | 36% | 0% | 0% |
PAT CAGR | 43% | 35% | 0% | 0% |
# | 1 Year | 3 Year | 5 Year | 10 Year |
---|---|---|---|---|
Share Price CAGR | NA% | NA% | NA% | NA% |
ROE Average | 22% | 13% | 13% | 13% |
ROCE Average | 21% | 15% | 14% | 14% |
#(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
---|---|---|---|---|
Shareholder's Funds | 237 | 239 | 294 | 366 |
Minority's Interest | 0 | 7 | -5 | -2 |
Borrowings | 244 | 421 | 465 | 453 |
Other Non-Current Liabilities | 20 | 25 | 33 | 37 |
Total Current Liabilities | 103 | 96 | 123 | 132 |
Total Liabilities | 603 | 789 | 909 | 986 |
Fixed Assets | 435 | 630 | 684 | 720 |
Other Non-Current Assets | 35 | 46 | 44 | 57 |
Total Current Assets | 134 | 113 | 180 | 209 |
Total Assets | 603 | 789 | 909 | 986 |
#(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
---|---|---|---|---|
Opening Cash & Cash Equivalents | 8 | 7 | 18 | 103 |
Cash Flow from Operating Activities | 74 | 123 | 137 | 176 |
Cash Flow from Investing Activities | -43 | -296 | -85 | -94 |
Cash Flow from Financing Activities | -32 | 185 | 33 | -51 |
Net Cash Inflow / Outflow | -1 | 12 | 85 | 31 |
Closing Cash & Cash Equivalent | 7 | 19 | 103 | 134 |
# | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
---|---|---|---|---|
Earnings Per Share (Rs) | 5.83 | -0.45 | 10.05 | 12.9 |
CEPS(Rs) | 10.92 | 5.59 | 17.16 | 19.72 |
DPS(Rs) | 0 | 0 | 1 | 1 |
Book NAV/Share(Rs) | 46.54 | 46.98 | 57.36 | 64.7 |
Core EBITDA Margin(%) | 17.84 | 13.81 | 20.92 | 22.56 |
EBIT Margin(%) | 12.65 | 8.34 | 16.51 | 19.16 |
Pre Tax Margin(%) | 7.1 | 0.32 | 10.52 | 14.42 |
PAT Margin (%) | 6.4 | -0.47 | 6.97 | 8.17 |
Cash Profit Margin (%) | 12 | 5.85 | 11.91 | 12.49 |
ROA(%) | 4.91 | -0.33 | 6.02 | 7.7 |
ROE(%) | 12.52 | -0.97 | 19.27 | 22.18 |
ROCE(%) | 11.52 | 6.91 | 16.66 | 21.07 |
Receivable days | 35.17 | 24.95 | 12.37 | 15.04 |
Inventory Days | 11.01 | 10.14 | 7.07 | 7.02 |
Payable days | 267.8 | 217.2 | 153.57 | 153.08 |
PER(x) | 0 | 0 | 0 | 0 |
Price/Book(x) | 0 | 0 | 0 | 0 |
Dividend Yield(%) | 0 | 0 | 0 | 0 |
EV/Net Sales(x) | 0.68 | 0.94 | 0.6 | 0.44 |
EV/Core EBITDA(x) | 3.74 | 6.41 | 2.81 | 1.85 |
Net Sales Growth(%) | 0 | 5.02 | 50.8 | 21.75 |
EBIT Growth(%) | 0 | -30.81 | 198.67 | 41.24 |
PAT Growth(%) | 0 | -107.75 | 2325.86 | 42.59 |
EPS Growth(%) | 0 | -107.75 | 2325.71 | 28.34 |
Debt/Equity(x) | 1.15 | 1.78 | 1.7 | 1.28 |
Current Ratio(x) | 1.3 | 1.18 | 1.46 | 1.58 |
Quick Ratio(x) | 1.16 | 1.04 | 1.34 | 1.44 |
Interest Cover(x) | 2.28 | 1.04 | 2.76 | 4.04 |
Total Debt/Mcap(x) | 0 | 0 | 0 | 0 |
# | Sep 2023 | Dec 2023 | Mar 2024 |
---|---|---|---|
Promoter | 40.91 | 40.91 | 40.91 |
FII | 4.62 | 3.97 | 4.17 |
DII | 12.69 | 13.93 | 14.16 |
Public | 41.78 | 41.19 | 40.75 |
Others | 0 | 0 | 0 |
Total | 100 | 100 | 100 |
# | Sep 2023 | Dec 2023 | Mar 2024 |
---|---|---|---|
Promoter | 2.68 | 2.68 | 2.68 |
FII | 0.3 | 0.26 | 0.27 |
DII | 0.83 | 0.91 | 0.93 |
Public | 2.74 | 2.7 | 2.67 |
Others | 0 | 0 | 0 |
Total | 6.56 | 6.56 | 6.56 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Sell or Purchase Share (Tentative Price)
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
You May Also Know About